ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BVXP Bioventix Plc

4,900.00
-50.00 (-1.01%)
27 Feb 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -50.00 -1.01% 4,900.00 4,800.00 5,000.00 4,950.00 4,900.00 4,950.00 1,638 09:04:54
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 12.82M 8.37M 1.6071 30.49 255.26M
Bioventix Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,950p. Over the last year, Bioventix shares have traded in a share price range of 3,450.00p to 5,060.00p.

Bioventix currently has 5,209,333 shares in issue. The market capitalisation of Bioventix is £255.26 million. Bioventix has a price to earnings ratio (PE ratio) of 30.49.

Bioventix Share Discussion Threads

Showing 1276 to 1299 of 1575 messages
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older
DateSubjectAuthorDiscuss
27/1/2021
09:51
Yes, this company has never been prolific with announcements... There are possibly two months before the next RNS, being the Interims at the end of March. Until then, we wait...
strollingmolby
27/1/2021
09:47
lets hope so - rubbish share been treading water for far too long!

Always useful to know when BVXP are being discussed elsewhere. So illiquid it normally signals a tick up.

igbertsponk
27/1/2021
09:44
David is welcome to continue posting such events on the thread as it is entirely relevant with BVXP being discussed there (this is why we are here after all), and also how some of us got to first hear of BVXP when the price was around £3. :)

So... are we going to reach an all-time high this week?

strollingmolby
27/1/2021
09:26
Timewasters!!!
igbertsponk
27/1/2021
09:00
Yeah, but you were one coming here slagging off Davidosh for doing it :-)
stepone68
27/1/2021
08:56
hi stepone68, a quick click on your username to view your posting history shows you're pretty fond of posting time-wasting nonsense yourself ;-) In fact I struggled to find a single piece of useful info in any of them. Quite a feat!!
luderitz
27/1/2021
08:48
hi Luderitz, a quick click on your username to view your posting history shows you're pretty fond of posting time-wasting nonsense yourself ;-) In fact I struggled to find a single piece of useful info in any of them. Quite a feat!!
stepone68
13/12/2020
22:32
Why waste our time posting that nonsense.
luderitz
10/12/2020
00:59
Just to mention that the Xmas special MelloMonday BASH may feature Bioventix on the 14th December and I think shareholders and potential investors will appreciate the analysis. There is also an interview with Keith Ashworth Lord who is a highly respected fund manager and well worth listening to. Keith's fund Castlefield are of course one of the largest shareholders in Bioventix.

The Mello Monday event starts at 6pm
The full programme is available on the website. In the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four/five companies are a Buy Avoid Sell or Hold at this current juncture in the markets.



All investors welcome and if you use the code MMTADVFN50 you will get a half price ticket. Great investor content and entertainment. We had nearly 400 investors attend last month so these are very popular.

davidosh
17/11/2020
12:17
The presentation packs and recording from our webinar with Bioventix can be found here for full members to view:

To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here:

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here:

sharesoc
01/11/2020
18:44
Well here's one I shall be watching this week for obvious reasons given some of the comments made above.
luderitz
31/10/2020
21:54
I wasn’t thanking you but just acknowledging that you were/are right.
luderitz
31/10/2020
21:48
No need to thank me
Hospital sales stall during lockdown which hits sales

onjohn
31/10/2020
21:48
No need to thank me
onjohn
31/10/2020
21:11
So it did.
luderitz
31/10/2020
20:36
fell under 30 quid last lockdown
onjohn
27/10/2020
19:45
interesting article on CAP website concerning hs troponin testing study done at Johns Hopkins public health department into stratifying risk in diabetes for MACE- seems can also be used to select for SGLT2 therapy...would greatly expand the market for hs troponin.
mw8156
27/10/2020
18:02
lomax99 - what on earth is the point of pasting that article which was published 12 months ago on 21st Oct. 2019 after last year's results before anyone had heard of Covid?
sharw
26/10/2020
22:15
? EPS for June 2020 was 138p.
trident5
26/10/2020
21:43
IC:Bioventix looks to next growth phaseUsing its sheep monoclonal antibody technology, Bioventix (BVXP) creates and supplies antibodies that can locate specific cells within human blood to make clinical diagnoses. More than two-thirds of revenue is derived from royalty and licensing fees when customers employ the group's antibodies in their diagnostic products – these payments jumped by 14 per cent to £6.3m in FY2019.Used to test for vitamin D deficiency, sales of its most popular 'vitD3.5H10' antibody increased by 27 per cent to £4.3m. Whilst pricing pressures are offseting volume growth in the more mature European and US markets, the group is benefitting from customers like South Korean Boditech tapping the burgeoning Asian market. Expecting more modest Vitamin D revenue growth moving forward, the group believes its troponin assays will become the stand-out driver of sales momentum. Still in the early roll-out stage, troponin sales only amounted to £120,000 but finnCap forecasts they could reach up to £3.5m by 2025.With a typical 4 to 10-year gap between the research phase and royalty revenue coming through, the current development pipeline aims to sustain growth beyond 2025. But expansion comes at a cost; a near-30 per cent surge in research and development costs during the period served to limit operating profit growth to just 1 per cent to £7m.finnCap anticipates adjusted pre-tax profit of £7.8m and EPS of 124.8p for the June 2020 year-end, rising to £8.6m and 136.8p in FY2021.There's a lot to like about Bioventix – high operating margins, positive free cash flow and an increasing return on capital employed. But with the shares trading at a lofty 25 times forecast 2020 earnings, we'd like to see a little more evidence that troponin can drive growth before diving in. Hold.
lomax99
25/10/2020
11:39
Current shareholders and potential investors may be interested in our webinar with Bioventix. More information and registration here:
sharesoc
21/10/2020
18:59
Thanks trident I’m aware of the spread as I sold out last week but managed to get the spread at a reasonable level.

Food for thought.

luderitz
21/10/2020
16:47
It will drop by the value of the dividend, subject to unknowable short term investor sentiment and you'll get hammered on the spread.
trident5
21/10/2020
16:38
I’m thinking of doing a divi play around ex-divi day and looking at their chart it seems to suggest a reduction after it which we know is usual.

Anyone else doing similar or have any relevant advice on the subject ?

luderitz
Chat Pages: 63  62  61  60  59  58  57  56  55  54  53  52  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com